Drug Database
GL

glucagon (LY 900018 / glucagon, Eli Lilly / Baqsimi)

✓ Approved

Amphastar Pharmaceuticals, Inc. · GCGR · Polypeptide

What is glucagon?

glucagon is a polypeptide developed by Amphastar Pharmaceuticals, Inc.. It is approved for therapeutic indications via inhaled or intramuscular (im) injection or intranasal.

Drug Profile

Brand NamesLY 900018, glucagon, Eli Lilly, Baqsimi
CompanyAmphastar Pharmaceuticals, Inc.
Drug ClassPolypeptide
Molecular TargetGCGR
RouteInhaled, Intramuscular (IM) Injection, Intranasal
StatusApproved

Mechanism of Action

Molecular Targets

glucagon acts on 1 molecular target:

GCGRglucagon receptor (GL-R, GGR)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

glucagon is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Metabolism and nutrition disordersHypoglycaemia✓ Approved

Related Research Articles

PubMedNature metabolism2026-09-19

m6A mRNA methylation regulates pancreatic α-cell plasticity.

De Jesus Dario F DF, Brown Natalie K NK, Fogarty Garrett G, Gabriel Guilherme G et al.

Pancreatic α-cells are central regulators of glucose and amino acid homeostasis, yet the mechanisms that preserve α-cell identity and function remain incompletely understood. N6-methyladenosine (m6A) is a widespread mRNA modification that is essential for β-cell biology and pancreatic endocrine differentiation. Here we show that m6A is a key regulator of α-cell function and plasticity. In α-cells, metabolic cues that stimulate glucagon secretion such as L-arginine increase METTL3, METTL14 and m6A levels. Loss of m6A impairs amino acid-stimulated glucagon secretion, disrupts α-cell identity programmes and induces metabolic rewiring. In mice, α-cell-specific Mettl14 deletion reduces α-cell mass, increases β-cell mass and promotes α-to-β-cell conversion, accompanied by the emergence of late β-like states with features of incomplete maturation. Mechanistically, m6A-eCLIP identifies Yy1 as a direct m6A-sensitive target, and elevated YY1 links m6A loss to signalling rewiring and erosion of α-cell identity. These findings identify m6A as a central regulator of α-cell state and reveal an epitranscriptomic mechanism controlling endocrine cell plasticity.

PubMedJournal of biophotonics2026-09-19

Enhancement of Harvested Islet Functionality Through Photostimulation.

Fowlds Kelli K, Darden Carly M CM, Lawrence Michael C MC, Cho Michael M

Allogeneic islet transplantation is a promising treatment for Type I diabetes, but its success is limited by islet loss during isolation, purification, and engraftment, resulting in variable long-term insulin independence. Our previous studies demonstrated that photobiomodulation (PBM) significantly enhances insulin and glucagon secretion in pancreatic cells, likely through modulation of ATP production and calcium signaling pathways involved in hormone release. Building on these mechanistic findings, we investigated whether PBM could similarly improve the functionality of whole islets before transplantation. Mouse islets were isolated by pancreatectomy, cultured ex vivo, and treated daily with PBM for 7 days. Fluorescence imaging and functional assays were used to assess insulin expression and secretion. PBM significantly enhanced insulin secretion, with an approximately twofold increase observed after 3 days of treatment. These findings support PBM as a promising, noninvasive approach for improving islet function before transplantation.

PubMedDiabetes technology & therapeutics2026-09-19

Association Between Continuous Glucose Monitoring Utilization and Glucagon-Like Peptide-1 Receptor Agonist Discontinuation in Type 2 Diabetes: A Real-World Study.

Wright Eugene E EE, Huang Eileen E, Bindal Anila A

Continuous glucose monitoring (CGM) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) when used jointly are associated with significant improvement in glycemic outcomes. However, it is unknown if using CGM enhances GLP-1 RA continuation. This study assesses the relationship between adherent CGM utilization and GLP-1 RA adherence among people living with type 2 diabetes (T2D) on nonintensive therapy. This retrospective matched-cohort study analyzed data from Inovalon® Insights administrative claims from March 1, 2017, to April 30, 2024, for adults aged ≥18 years diagnosed with T2D, treated with basal insulin or noninsulin therapy, and CGM-naïve before starting GLP-1 RA. Adherent CGM utilization was defined as having a proportion of days covered (PDC) ≥0.8 within 1-year post GLP-1 RA initiation. CGM users were matched with non-CGM users based on age, sex, race/ethnicity, basal insulin/noninsulin therapy, GLP-1 RA type, comorbidities, insurance type, and one fill/multiple refills of GLP-1 RA. The primary outcome was GLP-1 RA discontinuation over the 12-month observation period, which was defined as the first gap of ≥90 days without GLP-1 RA supply post-index. Kaplan-Meier model was used to estimate the time to discontinuation, and hazard ratios (HRs) were calculated using a multivariable Cox proportional hazards regression model. The study included 934 adherent CGM users matched with 3747 non-CGM users. One year post GLP-1 RA initiation, 68.4% (95% confidence interval [CI]: 65.5%-71.5%) of adherent CGM users remained on GLP-1 RA compared with 51.9% (95% CI: 50.3%-53.5%) of non-CGM users (P < 0.001). After adjusting for covariates, adherent CGM users were significantly less likely to discontinue GLP-1 RA compared to non-CGM users (HR: 0.56 [95% CI: 0.49-0.63], P < 0.001). This study suggests that adherent CGM utilization is associated with a significantly lower risk of GLP-1 RA discontinuation and may potentially enhance adherence to GLP-1 RA medication in people living with T2D on nonintensive therapy.

PubMedCurrent opinion in gastroenterology2026-09-19

GLP-1 agonists before endoscopy: separating fact from fiction.

Shah Tilak T

Glucagon-1 receptor agonists (GLP-1A) delay gastric emptying, which has raised concerns about heightened risk of increased residual gastric volume (RGV) despite appropriate fasting measures. RGV could increase risk of pulmonary aspiration during sedated procedures like upper endoscopy. The purpose of this review is to summarize literature on pathophysiology of delayed gastric emptying, and to highlight recent publications on risk of RGV and preventive strategies. GLP-1A delay gastric emptying via vagally mediated pathways; with long-term use this delay in gastric emptying is attenuated. GLP-1A significantly increases risk of RGV. Holding a dose of GLP-1A or continuing the medication with 24 h of clear liquids beforehand are both effective strategies. There is a trend towards greater effectiveness with the latter approach. In experienced hands, point of care ultrasound (POCUS) is highly accurate at identifying RGV before sedation. Recent studies have considerably enhanced our understanding of the pathophysiology and risk of RGV with GLP1A.

PubMedJACC. Asia2026-09-19

HFpEF in Asia-Clinical Characterization and Therapeutic Strategies.

Tromp Jasper J, Teng Tiew-Hwa Katherine TK, Tay Wan Ting WT, Chandramouli Chanchal C et al.

Heart failure with preserved ejection fraction (HFpEF) prevalence is increasing in Asia, driven by aging populations and rising cardiometabolic risk. Asian patients with HFpEF present a decade earlier than Western counterparts, carry a disproportionate burden of diabetes, chronic kidney disease, and visceral adiposity at lower body mass index thresholds, and exhibit marked regional heterogeneity in clinical subtypes and outcomes. Diagnosis remains challenging, as algorithms derived in Western populations perform suboptimally in Asian patients, and access to echocardiography and natriuretic peptide testing is highly variable across the region. Artificial intelligence-enabled tools can bridge these diagnostic gaps. Therapeutically, sodium-glucose cotransporter 2 inhibitors demonstrate consistent benefit across Asian subgroups, whereas glucagon-like peptide-1 receptor agonists and nonsteroidal mineralocorticoid receptor antagonists represent important emerging options, though evidence in lean Asian subtypes remains limited. This review examines the diagnosis, clinical heterogeneity, clinical outcomes, and treatment of HFpEF across Asia, highlighting priorities for future research and quality of care.

PubMedFood science and biotechnology2026-09-19

Carbohydrate-mediated appetite regulation: physiological mechanisms, gut hormone-based therapies, and nutritional interventions.

Park Je-Hyun JH, Song Young-Bo YB, Kang Yu-Ra YR, Lee Byung-Hoo BH

Recently, glycemic carbohydrates have received increasing attention for their roles in regulating postprandial glycemic responses and appetite through coordinated digestive, hormonal, and neural mechanisms. This review provides an overview of how carbohydrate digestion rate influences gut-derived hormonal responses and appetite regulation. The physiological roles of gut hormones, such as glucagon-like peptide-1 (GLP-1), peptide YY (PYY), and glucose-dependent insulinotropic polypeptide (GIP), are discussed in relation to the nutrient-sensing, gut-brain axis, and intestinal feedback (ileal and colonic brakes) mechanisms. Furthermore, this review highlights food-level approaches for modulating carbohydrate digestion rate using structurally modified carbohydrates with slow digestive properties. Phytochemicals and non-starch polysaccharides are also discussed as inhibitory factors in carbohydrate digestion and absorption. This work offers a theoretical framework for future research aimed at long-term appetite regulation through dietary strategies rather than therapeutic interventions, thereby contributing to sustained glycemic control and long-term metabolic health.

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about glucagon